AACR Names T-Cell ALL Researcher as a 2023 Next Gen Star
By Anastasia Tikhonova, PhD - May 8, 2023Anastasia Tikhonova, PhD, was named a 2023 NextGen Star by the American Association for Cancer Research (AACR). Dr. Tikhonova, whose research is in T-cell acute lymphoblastic leukemia (ALL), talks about the honor of being awarded the title in this video interview.
Post Tags:AACR 2023
Advertisement
Related Posts
Dr. Hill and colleagues presented their research on the CAR-T manufacturing approach during the 2023 ASCO meeting.
Most patients (83%) responded to the treatment, with 63% having a complete response.
The study evaluated an NGS assay and its correlation with RT-PCR assay results for BCR::ABL in patients with Ph+ ALL.
The two-year PFS rate was 58.2%, while the five-year PFS rate was 44% at a median follow-up of 92.8 months.
The 18-month overall survival rate was 75%, while the event-free survival rate was 53.1%.
Advertisement
Advertisement
Editorial Board
Sagar Lonial, MD, FACPEditor-in-Chief | Chief Medical Officer of Winship Cancer Institute at Emory University School of Medicine
Guillermo Garcia-Manero, MDAssociate Editor | Chief, Section of Myelodysplastic Syndromes, The University of Texas MD Anderson Cancer Center
Elias Jabbour, MDAssociate Editor | Professor in the Department of Leukemia, Division of Cancer Medicine, MD Anderson Cancer Center
Kami Maddocks, MDAssociate Editor | Professor of Clinical Internal Medicine in the Division of Hematology at The Ohio State University
Thomas Martin, MDAssociate Editor | Clinical Research Director, UCSF Helen Diller Family Comprehensive Cancer Center
Jerald Radich, MDAssociate Editor | Professor in the Clinical Research Division and Kurt Enslein Endowed Chair at Fred Hutch
Laurie Sehn, MD, MPHAssociate Editor | Clinical Professor of Medical Oncology, British Columbia Cancer Centre for Lymphoid Cancer
670 Madison Ave.
Manalapan, NJ 07726